Data as of Sep 12, 2026. Both funds on the fields they both publish, from the same sources.
XBI vs XLV: how they differ
XBI and XLV hold 6% of their weight in the same names, and XBI returned more over the year.
State Street(R) SPDR(R) S&P(R) Biotech ETF and State Street(R) Health Care Select Sector SPDR(R) ETF.
What they hold in common
By the books each fund has filed, XBI and XLV hold 6% of their money in the same securities at the same weight.
| Holding | XBI | XLV |
|---|---|---|
| Vertex Pharmaceuticals Inc | 1.06% | 2.20% |
| AbbVie Inc | 1.04% | 7.76% |
| Amgen Inc | 1.00% | 3.41% |
| Gilead Sciences Inc | 0.97% | 2.74% |
| Regeneron Pharmaceuticals Inc | 0.96% | 1.09% |
| Biogen Inc | 1.03% | 0.56% |
| Moderna Inc | 1.41% | 0.43% |
| Incyte Corp | 1.00% | 0.33% |
| Only in XBI | Only in XLV |
|---|---|
| Apogee Therapeutics Inc 1.49% | Eli Lilly & Co 16.56% |
| Twist Bioscience Corp 1.41% | Johnson & Johnson 10.67% |
| Oruka Therapeutics Inc 1.38% | UnitedHealth Group Inc 6.59% |
| Kymera Therapeutics Inc 1.36% | Merck & Co Inc 5.54% |
| Viking Therapeutics Inc 1.31% | Thermo Fisher Scientific Inc 3.25% |
| Praxis Precision Medicines Inc 1.29% | Abbott Laboratories 2.76% |
| Erasca Inc 1.27% | Intuitive Surgical Inc 2.46% |
| Revolution Medicines Inc 1.21% | Pfizer Inc 2.40% |
Weight overlap is an ETFIQ calculation: for every security both funds hold, the smaller of the two weights, summed. Above 50%, holding both is close to holding one of them twice. Holdings dated Jun 30, 2026.
| XBI State Street(R) SPDR(R) S&P(R) Biotech ETF | XLV State Street(R) Health Care Select Sector SPDR(R) ETF | |
|---|---|---|
| Where it sits | Core index fund | Core index fund |
| Issuer | State Street | State Street |
| What it is | SPDR S&P Biotech | Health care |
| Total return, 1 year | +64.0% | +20.4% |
| S&P 500 over the same days | +17.5% | +17.5% |
| Gap to the S&P 500 | +46.5 pts | +2.9 pts |
| Expense ratio | 0.35% | 0.08% |
| Already in the S&P 500 | 8.5% | 100.0% |
| Holdings | 150 | 59 |
XBI in plain words
XBI is an index equity fund tracking the SPDR S&P Biotech. Over the year to Sep 11, 2026 it returned +64.0% with distributions reinvested, against +17.5% for the S&P 500 and +23.0% for the Nasdaq-100. The prospectus expense ratio is 0.35% a year. By its holdings filed for Jun 30, 2026, 8% of the fund by weight is stocks the S&P 500 also holds, across 150 positions, with the top ten at 13.3%. It sat 9.6% below its high of Feb 8, 2021 on Sep 11, 2026.
XLV in plain words
XLV is an index equity fund tracking the Health care. Over the year to Sep 11, 2026 it returned +20.4% with distributions reinvested, against +17.5% for the S&P 500 and +23.0% for the Nasdaq-100. The prospectus expense ratio is 0.08% a year. By its holdings filed for Jun 30, 2026, 100% of the fund by weight is stocks the S&P 500 also holds, across 59 positions, with the top ten at 61.7%. It sat 5.9% below its high of Aug 19, 2026 on Sep 11, 2026.
Questions people ask
- Which returned more over the last year, XBI or XLV?
- In the year to Sep 12, 2026, with distributions reinvested, XBI returned +64.0% and XLV returned +20.4%, so XBI returned more. One year is one year; the longer windows are in the table.
- Which is cheaper, XBI or XLV?
- XBI charges 0.35% a year and XLV charges 0.08%, so XLV is cheaper. Fees come from each fund's prospectus.
- How much do XBI and XLV overlap with the S&P 500?
- By their latest filed holdings, 8% of XBI and 100% of XLV by weight is stocks the S&P 500 already holds. Between the two funds, 6% of their books are the same securities at the same weight.
Other comparisons
Where to next
Where these figures came from
ETFIQ links to the documents behind every figure. It is not affiliated with any issuer, and a link is not an endorsement.
Cite this page. ETFIQ, XBI against XLV, data as of Sep 12, 2026. https://etfiq.com/compare/any/XBI-XLV Free to use with attribution; the underlying files are at Open data.
A comparison is not a recommendation. Standards and sources